dasatinib

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist

Related drugs:

‹

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 1 week (New D) dasatinib + lapatinib Sensitive : D PLoS One - 1wk	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 1 week dasatinib + lapatinib Sensitive : D PLoS One - 1 week - (New D)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 V299L	Acute Lymphocytic Leukemia	BCR-ABL1 V299L	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317I	Acute Lymphocytic Leukemia	BCR-ABL1 F317I	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
PDGFRA fusion	Childhood B Acute Lymphoblastic Leukemia	PDGFRA fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
FGFR fusion	Childhood B Acute Lymphoblastic Leukemia	FGFR fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
BCR-ABL1 F317L	Chronic Myeloid Leukemia	BCR-ABL1 F317L	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
BCR-ABL1 V299L	Chronic Myeloid Leukemia	BCR-ABL1 V299L	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315A	Chronic Myeloid Leukemia	BCR-ABL1 T315A	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317I	Chronic Myeloid Leukemia	BCR-ABL1 F317I	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317V	Chronic Myeloid Leukemia	BCR-ABL1 F317V	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317C	Chronic Myeloid Leukemia	BCR-ABL1 F317C	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317L	Acute Lymphocytic Leukemia	BCR-ABL1 F317L	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317C	Acute Lymphocytic Leukemia	BCR-ABL1 F317C	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317V	Acute Lymphocytic Leukemia	BCR-ABL1 F317V	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315A	Acute Lymphocytic Leukemia	BCR-ABL1 T315A	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
BCR-ABL1 L248V	Chronic Myeloid Leukemia	BCR-ABL1 L248V	Chronic Myeloid Leukemia	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B
BCR-ABL1 G250E	Chronic Myeloid Leukemia	BCR-ABL1 G250E	Chronic Myeloid Leukemia	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B
BCR-ABL1 Q252H	Chronic Myeloid Leukemia	BCR-ABL1 Q252H	Chronic Myeloid Leukemia	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B
BCR-ABL1 E255K	Chronic Myeloid Leukemia	BCR-ABL1 E255K	Chronic Myeloid Leukemia	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B
BCR-ABL1 F359C	Chronic Myeloid Leukemia	BCR-ABL1 F359C	Chronic Myeloid Leukemia	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B
BCR-ABL1 Y253H	Chronic Myeloid Leukemia	BCR-ABL1 Y253H	Chronic Myeloid Leukemia	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B

dasatinib

Associations
(214)

Associations
(214)

dasatinib

Associations(214)

Associations(214)

Associations
(214)

Associations
(214)